Ixabepilone is the first in a new class of antineoplastic agents, the epothilones and their analogs. This international, randomized, phase II trial assessed two administration schedules of ixabepilone as second-line therapy in patients with non-small-cell lung cancer (NSCLC).
INTRODUCTION
The prognosis for lung cancer patients remains poor, with only 15% of patients surviving more than 5 years from diagnosis. 1 The currently accepted first-line chemotherapy for patients with stage IIIB and IV non-small-cell lung cancer (NSCLC) includes a platinum-based agent in combination with another cytotoxic agent such as vinorelbine, gemcitabine, a taxane, or irinotecan (in Japan only). This is associated with symptom improvement, but only moderate survival advantages when compared with best supportive care alone.
2-5
Three second-line therapies are currently approved by the US Food and Drug Administration for patients whose tumors have progressed after platinum-based treatments: docetaxel, erlotinib, and pemetrexed. Despite some survival advantages with these agents, objective responses are uncommon. 6, 7 Therefore, there is a pressing need for effective second-line treatments for NSCLC patients who experience disease progression after platinum-based chemotherapy. With tumor resistance (eg, through intrinsic and acquired multidrug resistance or alterations in tubulin isoform expression) as the principle factor limiting the effectiveness of existing agents, development of agents less susceptible to these resistance mechanisms would be of particular benefit.
The epothilones and their analogs are a novel class of antimicrotubule agents derived from the myxobacterium Sorangium cellulosum. These macrolides promote tumor cell death by arresting cell division, which leads to apoptosis. Ixabepilone (BMS-247550), the first semisynthetic analog, was designed to optimize the characteristics of naturally occurring epothilone B. Preclinically, ixabepilone has demonstrated reduced susceptibility to multiple tumor resistance mechanisms, including efflux transporters such as multidrug resistance-associated protein 1 and P-glycoprotein, which are involved in acquired and intrinsic tumor resistance. 8, 9 Clinical activity has been demonstrated with ixabepilone in phase II trials in a broad range of tumors that, in many cases, had been heavily pretreated with and/or were resistant to prior therapies, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and a phase III trial is currently assessing ixabepilone in the treatment of metastatic breast cancer. Results also are eagerly awaited from a phase II study to identify markers that may predict response to ixabepilone in the neoadjuvant setting. 10 This study evaluated two administration schedules of ixabepilone in patients with NSCLC whose disease had progressed after one prior regimen of a platinum-based chemotherapy for stage III/IV NSCLC, or for recurrent metastatic disease. We report results for patients who received either 32 mg/m 2 as a 3-hour infusion on day 1 of a 3-week cycle (arm A) or 6 mg/m 2 as a 1-hour infusion on days 1 to 5 of a 3-week cycle (arm B). The initially planned dose for this study was 50 mg/m 2 as a 1-hour infusion every 21 days, but this was soon amended to 40 and then 32 mg/m 2 , after unacceptable toxicities were observed. Because of the early dose amendments and the prior presentation of the 50 mg/m 2 dose data, 21 results for the 40 and 50 mg/m 2 cohorts are not reported here.
PATIENTS AND METHODS

Study Design
This was a randomized, multicenter, open-label, phase II study of ixabepilone in patients with NSCLC who had received one prior platinumcontaining first-line chemotherapy regimen. The protocol was approved by local ethics committees and conducted in accordance with the US Food and Drug Administration, the International Conference on Harmonization Guidelines for Good Clinical Practice, and the Declaration of Helsinki.
Patients
Patients age Ն 18 years with histologically/cytologically confirmed NSCLC (stage III/IV or metastatic recurrent disease), with bidimensionally measurable disease progression after one prior cisplatin-or carboplatin-based chemotherapy regimen, a performance status of 0 to 1, and life expectancy of Ն 12 weeks were eligible. Adequate hematologic (absolute neutrophil count Ն 2,000 cells/L, platelets Ͼ 125,000/L), hepatic (serum bilirubin Յ 1.5ϫ institutional upper limits of normal [ULN], ALT Յ 2.5ϫ ULN [Յ 5ϫ ULN in the presence of hepatic metastases]), and renal function (serum creatinine Յ 1.5ϫ ULN) were required. Patients were excluded if they had received more than one prior chemotherapy regimen (except [neo]adjuvant chemotherapy); had grade Ն 2 neuropathy (according to National Cancer Institute Common Toxicity Criteria); or had known brain metastases. All patients provided written informed consent before study entry.
Treatment Schedule
On the basis of phase I studies, 22,23 ixabepilone initially was administered at 50 mg/m 2 as a 1-hour infusion every 21 days. The study subsequently was modified twice by amendments. The first amendment stopped enrollment into the 50 mg/m 2 cohort because of neurotoxicity observed in this and other phase II studies. This amendment instituted a randomized enrollment scheme with two arms: 40 mg/m 2 as a 3-hour infusion on day 1 of a 3-week cycle, or 6 mg/m 2 as a 1-hour infusion daily for 5 consecutive days every 3 weeks. The latter schedule was pursued based on a phase I trial, which showed a low incidence of neuropathy at the recommended phase II dose. 24 The randomization used a permuted block procedure, stratified for prior taxane therapy (therapy v no therapy). However, after 19 patients had been enrolled into the 40 mg/m 2 cohort, a second amendment reduced the starting dose to 32 mg/m 2 in this group because of unacceptable rates of mucositis and neutropenia. Patients in arm B were accrued, therefore, while patients in the alternative treatment arm were being enrolled on 40 mg/m 2 and subsequently 32 mg/m 2 doses. This report focuses on patients treated with 32 mg/m 2 (hereafter referred to as arm A), or 6 mg/m 2 as a 1-hour infusion daily for 5 consecutive days every 3 weeks (arm B), with the aim of identifying the treatment schedule with the best safety-efficacy balance (Fig 1) . Results for the amended 40 and 50 mg/m 2 cohorts are not presented here. Treatment continued every 3 weeks for Յ 18 cycles, unless there was unacceptable toxicity, progressive disease (PD; 25% or greater increase in overall sum of the products of diameters of all target lesions in reference to the smallest sum recorded at or after baseline, or unequivocal progression of existing nontarget lesions overall or presence of new lesions), and/or other discontinuation criteria. Patients with a complete response (disappearance of all clinical and radiological evidence of target lesions and nontarget lesions with no new lesions confirmed on at least two consecutive observations at least 4 weeks apart) received no more than four treatment cycles. Patients with stable disease (failure to observe complete response or partial response, in the absence of any progressive or new lesions, confirmed on at least two consecutive observations at least 4 weeks apart) or partial response (50% or greater decrease in overall sum of the products of diameters of all target lesions in reference to the baseline sum, persistence of one or more nontarget lesions with no new lesions confirmed on at least two consecutive observations at least 4 weeks apart) were treated until PD or for Յ 18 cycles. All patients were premedicated with oral H 1 /H 2 blockers; antiemetics were not administered routinely. Patients were assessed every 3 months after discontinuation.
Dose reduction was permitted in the event of grade 4 neutropenia lasting Ն 7 days; febrile neutropenia; platelets less than 25,000/L; grade Ն 3 thrombocytopenia with bleeding requiring transfusion; more than 1 week delay in re-treatment due to drug toxicity; grade 3 nausea/vomiting, diarrhea, or stomatitis; grade 2 neuropathy (motor or sensory) lasting Ն 7 days; or grade 3 neuropathy or other grade Ն 3 toxicities.
Colony-stimulating factors such as granulocyte colony-stimulating factor were used at the discretion of the investigator. Growth factor was not administered for 24 hours before or after cytotoxic chemotherapy, including ixabepilone.
Study Assessments
The primary objective was to assess clinical activity of ixabepilone, measured by objective response rate (ORR). Tumor evaluations (physical examination and imaging studies) were performed at baseline and after every two cycles. Response was assessed according to modified WHO criteria, 25 with confirmation of responses on two consecutive occasions, Ն 4 weeks apart. Secondary efficacy objectives were duration of response (calculated for all responders and defined as the period between the first day of treatment and the date PD was first noted, or death); progressionfree survival (time from the first day of treatment until the first date of PD or death was reported); and overall survival (OS). Toxicities were evaluated continuously, hematology was evaluated weekly, and serum chemistry was evaluated before each cycle. Safety analyses were conducted on all treated patients who received at least one dose of ixabepilone. Patients who experienced any drug-related toxicities were followed up at least every 4 weeks until all drug-related toxicities were resolved, stabilized, returned to baseline, or deemed irreversible. Toxicity was classified according to the National Cancer Institute Common Toxicity Criteria, version 2.0.
Statistical Analysis
Given that this was a noncomparative randomized phase II trial, no formal statistical comparisons between treatment arms were made. A Simon optimal two-stage design 26 was used in both treatment arms to test whether the ORR was of clinical interest. For each arm, an ORR more than 7% was considered of clinical interest. In the first stage, 27 response-assessable patients were to be accrued. If there were no more than two responders at the end of the first stage, enrollment onto the treatment arm was to be terminated. Otherwise, if there were at least three responses, an additional 43 response-assessable patients were to be accrued in the second stage. With this design, there was less than a 10% chance of stopping at the end of the first stage if the true response rate was Ն 20%. Stopping at the end of the first stage would indicate that ixabepilone administered in the treatment arm was not worth investigating further in this population. A 10% inassessability rate was assumed for a total of about 77 patients to be enrolled onto each treatment arm.
A modification of the method to adjust for the Simon two-stage design was used, in which analyses consisted of the point estimate for ORR and the two-sided exact 95% CI for arms A and B. Discrete variables were summarized, with the number and proportion of patients in each category. Median duration of response, progression-free survival, and OS, with 95% CIs, were calculated for each cohort using the Kaplan-Meier product-limit method.
27 Continuous variables were summarized descriptively (median and range). Time to response was presented using univariate statistics (median and range values).
RESULTS
Patients
In total, 201 patients were enrolled from 29 study centers (United States, 15; France, five; Spain, four; Canada, three; Belgium, one; and Italy, one center). Of these, 31 patients were enrolled to receive 50 mg/m 2 ixabepilone, 30 of whom were treated. After the first protocol amendment, 19 patients were randomly assigned to 40 mg/m 2 ; all were treated. After the second protocol amendment (to 32 mg/m 2 ), 77 patients were randomly assigned to arm A, all of whom were treated. Seventy-four patients were randomly assigned to arm B, of whom 69 received treatment. Here we report results for patients receiving 32 mg/m 2 (arm A), and all patients in 6 mg/m 2 (arm B), regardless of whether they were randomly assigned concurrently with patients receiving 40 or 32 mg/m 2 (Fig 1) . Baseline demographic and clinical characteristics are summarized in Table 1 . Approximately half of the enrolled patients had received prior radiotherapy; all had received one prior platinum-based regimen either in the metastatic, adjuvant, neoadjuvant, or metastatic and adjuvant setting. Approximately half of patients had received prior taxane therapy in both arms.
Patients in arm A received a median of three cycles (range, one to 17 cycles); median cumulative dose and dose-intensity were 96.2 mg/m 2 (range, 26.5 to 542 mg/m 2 ) and 10.6 mg/m 2 /wk (range, 6.9 to 11.1 mg/m 2 /wk), respectively. Patients in arm B received a median of two cycles (range, one to 14 cycles), and the median cumulative dose and dose-intensity were 61.5 mg/m 2 (range, 5.9 to 411.3 mg/m 2 ) and 9.9 mg/m 2 /wk (range, 2.0 to 10.5 mg/m 2 /wk), respectively. No patient received the maximum permitted number of cycles (18 cycles), although one patient received 17 courses of ixabepilone. Most discontinuations in arms A and B were due to disease progression or relapse (64% and 57%, respectively), or clinical deterioration (9% and 6%, respectively). 
Efficacy
The ORR was 14.3% (95% CI, 7.5% to 25.8%) and 11.6% (95% CI, 5.5% to 24.8%) for arms A and B, respectively (Table 2) . Of those who responded, the majority did so after two cycles of treatment. Median duration of response was 8.7 months (95% CI, 5.3 to 9.5 months) for arm A and 9.6 months (95% CI, 6.1 to 19.7 months) for arm B. Thirteen of the 19 responders (68%) were without disease progression for more than 6 months, including three patients who were progression-free for more than 12 months.
Median time to progression for assessable patients was 2.1 months (95% CI, 1.4 to 2.8 months) for arm A and 1.5 months (95% CI, 1.4 to 2.8 months) for arm B. Median OS was 8.3 months (95% CI, 5.8 to 11.5 months) for arm A and 7.3 months (95% CI, 5.7 to 11.7 months) for arm B. The 1-year survival rate in both cohorts was 38%. A total of 22 patients (11 in each cohort) survived more than 2 years, nine of whom were responders.
In arm A, 31 patients had received prior taxane therapy in the metastatic setting, four of whom (13%) responded to ixabepilone (Table 3) . Moreover, one patient in arm A who received prior adjuvant paclitaxel had a complete response to ixabepilone (Table 3) . In arm B, two (6%) of 32 patients previously treated with a taxane in the metastatic setting responded to ixabepilone. Twenty-seven patients in arm A had experienced PD within 1 month of receiving their last dose of platinum-based chemotherapy in the metastatic setting (platinum refractory); of these, four (15%) responded to ixabepilone. Although not considered platinum refractory in this study, of the 18 patients who experienced relapse between 1 and 4 months after receiving platinum-based therapy, three patients (17%) responded to ixabepilone. No patients with prior platinum therapy for metastatic disease in arm B responded to ixabepilone.
On discontinuation of ixabepilone, 50 (65%) of 77 patients in arm A and 39 (57%) of 69 patients in arm B received subsequent chemotherapy. Among the 19 responders, 14 received subsequent chemotherapy, including seven who were treated with agents with demonstrated efficacy in platinum-failed NSCLC: docetaxel (five Abbreviation: ECOG, Eastern Cooperative Oncology Group. Table 4 ). The most frequent (Ն 5%) grade 3/4 treatment-related AEs included peripheral sensory neuropathy, vomiting, and fatigue. AEs led to discontinuation of study therapy in 15 (19%) and 17 (25%) patients in arms A and B, respectively.
Sensory neuropathy of any grade occurred in 29 of 77 (38%) and 20 of 69 (29%) patients in arms A and B, respectively (Table 4) . It was primarily mild to moderate (grade 1/2), with grade 3 occurrences reported in four patients each in arms A and B, and only one grade 4 case reported (arm A). Sensory neuropathy was mostly reversible; grade 3/4 neuropathy resolved or improved to grade 1 in four of five and three of four patients in arms A and B, respectively (Fig 2) . Three patients in each cohort discontinued due to sensory neuropathy.
Hematologic AEs. Hematologic abnormalities in both treatment arms were manageable. Grade 3 and 4 neutropenia incidences were 16% and 12%, respectively, in arm A, and 11% and 6%, respectively, 13  17  1  1  0  13  19  0  0  Constipation  11  14  1  1  0  12  17  0  0  Stomatitis/pharyngitis  9  12  2  3  0  10  14  1  1  0  Taste disturbance  3  4  0  0  8  12  0  0  Mucositis  5  6  0  0  5  7  0  0  Constitutional symptoms  Fatigue  46  60  4  5  0  38  55  6  9  0  Fever  5  6  0  0  6  9  0  0  Dermatology/skin  Alopecia  34  44  0  0  24  35  0  0  Nail changes  4  5  0  0  6  9  0  0  Injection site reaction  5  6  0  0  5  7  0  0  Rash/desquamation  5  6  0  0  0  0  0  Pain  Myalgia  17  22  1  1  0  20  29  1  1  0  Arthralgia  17  22  2  3  0  6  9  0  0  Headache  5  6  0  0  2  3  0  0  Pain, in arm B (Table 4) . Treatment-related febrile neutropenia occurred in five patients in arm A and in one patient in arm B, two of whom (both in arm A) discontinued treatment as a result. WBC growth factor support, in the form of filgrastim, was provided to five patients in arm A and two patients in arm B.
There was one death in arm A as a result of pneumonia/respiratory failure, and one in arm B as a result of pulmonary pneumonitis, infection without neutropenia, mucositis, confusion, and hypoxia, both of which were considered related to ixabepilone therapy.
DISCUSSION
Treatment options for advanced NSCLC remain limited. In patients who have already experienced treatment failure after first-line chemotherapy, currently approved second-line therapies have resulted in survival benefits, but ORRs generally are low. 6, 28 Novel antineoplastic agents with the capacity to overcome mechanisms of tumor resistance offer the promise of superior anticancer activity in this difficult-totreat patient group.
In this study of patients with stage III/IV NSCLC whose disease had progressed after one platinum-based chemotherapy, ixabepilone treatment at either 32 mg/m 2 (arm A) or at 6 mg/m 2 for 5 consecutive days (arm B) resulted in clinically relevant activity and an acceptable safety profile. The ORRs in this study compare favorably with those for second-line docetaxel, pemetrexed, and erlotinib in similar populations in phase III studies. However, caution should be exercised with such a comparison, given that the study reported herein was a phase II study. In two similarly sized phase III studies comparing docetaxel with either best supportive care 28 or vinorelbine/ ifosfamide, 29 ORR was between 6.7% and 10.8%. In a phase III trial of second-line pemetrexed or docetaxel after prior platinum/paclitaxel treatment, ORRs were 9.1% and 8.8%, respectively. 7 Similarly, in a randomized phase III trial comparing erlotinib with placebo in NSCLC patients after one or two prior chemotherapy regimens (93% of patients had received prior platinum-based therapy), erlotinib treatment resulted in an ORR of 8.9%. 6 In addition to the encouraging ORR rates, median OS seen in this study (8.3 and 7.3 months in arms A and B, respectively) was comparable to that in the aforementioned phase III studies. 6, 7, 28 In the second-line pemetrexed study described in the preceding paragraph, 7 docetaxel-pretreated patients were excluded, and only one fourth of patients were pretreated with paclitaxel. However, with the caveat of a phase II versus phase III study comparison, it is of note that approximately half of the patients on our study were treated previously with taxanes, and that responses (including one complete response) to ixabepilone were seen in patients who had received prior taxanes. Ixabepilone also demonstrated activity in arm A in the subset of patients with platinum-refractory tumors (ie, PD within 1 month of therapy in the metastatic setting) and in patients who had experienced disease progression within 1 to 4 months of platinum therapy. The encouraging responses seen in this study may be explained by the reduced susceptibility of ixabepilone to multiple tumor resistance mechanisms. In addition to its reduced susceptibility to efflux pump proteins, 9 ixabepilone affects the microtubule dynamics of multiple ␤-tubulin isoforms, including ␤III tubulin, 8 the overexpression of which is associated with clinical taxane resistance.
Both treatment arms in this study were associated with acceptable safety. Myelosuppression (primarily neutropenia and leukopenia) was manageable. Overall, less than one third of patients in either arm had grade 3/4 AEs considered related to ixabepilone. Neuropathy, one of the more common nonhematologic toxicities, was primarily sensory, generally mild to moderate in severity, and mostly reversible. Common ixabepilone-related AEs were similar to those noted in phase II trials of ixabepilone in patients with other advanced cancers. 12, 16, 17, 20 No obvious patterns in frequency or type of AEs emerged that might suggest one schedule was better tolerated than the other; rather, future preference might be based on the convenience of the arm A regimen.
In conclusion, single-agent ixabepilone administered in two dosing regimens demonstrated encouraging clinical activity and an acceptable safety profile in patients with advanced NSCLC whose tumors had failed prior platinum-based chemotherapy. The fact that a large proportion of patients in this trial were pretreated with taxanes, or had experienced disease progression after initial platinum-based therapy, suggests that ixabepilone may represent a novel therapeutic option for patients with advanced NSCLC. Given that ixabepilone demonstrated antineoplastic activity across all regimens used in this second-line setting, confirmatory studies of ixabepilone in NSCLC are warranted.
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